Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors

Introduction: While acute Coronavirus disease 2019 (COVID-19) affects the cardiovascular (CV) system according to recent data, an increased CV risk has been reported also during long-term follow-up (FU). In addition to other CV pathologies in COVID-19 survivors, an enhanced risk for arrhythmic event...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiedler, Lukas, Motloch, Lukas J., Dieplinger, Anna-Maria, Jirak, Peter, Davtyan, Paruir, Gareeva, Diana, Badykova, Elena, Badykov, Marat, Lakman, Irina, Agapitov, Aleksandr, Sadikova, Liana, Pavlov, Valentin, Föttinger, Fabian, Mirna, Moritz, Kopp, Kristen, Hoppe, Uta C., Pistulli, Rudin, Cai, Benzhi, Yang, Baofeng, Zagidullin, Naufal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266094/
https://www.ncbi.nlm.nih.gov/pubmed/37324463
http://dx.doi.org/10.3389/fphar.2023.1093396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266094/
https://www.ncbi.nlm.nih.gov/pubmed/37324463
http://dx.doi.org/10.3389/fphar.2023.1093396

Ejemplares similares